Company 3 Revenue and Competitors
Estimated Revenue & Valuation
- Company 3's estimated annual revenue is currently $300M per year.
- Company 3's estimated revenue per employee is $71,616
Employee Data
- Company 3 has 4189 Employees.
- Company 3 grew their employee count by 32% last year.
Company 3 Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 98 | -1% | N/A | N/A |
#2 | $1.7M | 39 | 3% | N/A | N/A |
#3 | $3.5M | 74 | 32% | N/A | N/A |
#4 | $7.5M | 49 | -8% | N/A | N/A |
#5 | N/A | 43 | 48% | N/A | N/A |
#6 | $35M | 31 | 0% | N/A | N/A |
#7 | $7.5M | 108 | 33% | N/A | N/A |
#8 | $15M | 69 | 1% | N/A | N/A |
#9 | $15M | 289 | 20% | N/A | N/A |
#10 | $15M | 90 | 23% | N/A | N/A |
What Is Company 3?
Company 3 is a comprehensive post production facility for features, commercials and music videos. Known for its creative color artistry, pioneering technology and global reach, Company 3 is trusted to deliver a quality product every time. It is home to one of the largest and most talented pools of colorists and visual effects artists working in post production today with a client list that includes many of the most respected and talented film and entertainment professionals in the industry.
keywords:N/AN/A
Total Funding
4189
Number of Employees
$300M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company 3 News
Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug (IND) indication to date.
3 tech companies with great culture ... When you're thinking about making a job move, there are a few things to consider: that the role is a match...
Many companies have launched their own internal software companies tasked with developing new products for the market.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1619.1M | 4511 | -5% | $93.9M |
#2 | $1143M | 4609 | 29% | $85.3M |
#3 | $2534.7M | 6565 | -18% | $233.5M |
#4 | $9050M | 11081 | 5% | N/A |
#5 | N/A | 12339 | 20% | $7.8B |